\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Prognostic Factors Affecting Management of Liposarcoma}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2017-01-15 (revised: 15 January 2017)} \def\TheID{\makeatother } \def\TheDate{2017-01-15} \title{Prognostic Factors Affecting Management of Liposarcoma} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Cary Fletcher} \affil[1]{ Saint Anns Bay Regional Hospital, Saint Ann,} \renewcommand\Authands{ and } \date{\small \em Received: 8 December 2016 Accepted: 4 January 2017 Published: 15 January 2017} \maketitle \begin{abstract} Soft tissue sarcomas account for 1% of all neoplasms, with the second commonest being liposarcomas. Liposarcomas in the popliteal fossa often grows to a large size, as neither the patient nor the clinician will initially be able to palpate the tumour due to its depth in the tissues and the fact that the tumour is often low grade. Its size often does not facilitate the ability to resect the mass with wide margins. The following article discusses prognostic factors for liposarcomas with regards to histological subtype, anatomical distribution, resection margins and neoadjuvant therapy. \end{abstract} \keywords{liposarcoma, prognostic factors, management.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction II.}]{Introduction II.} \section[{Case Presentation}]{Case Presentation}\par A 48 year old male presented to the Orthopaedic outpatient clinic with a one year history of a painless mass in the back of the right knee. This mass gradually increased in size. There was no history of numbness or weakness in the right lower limb. He denied having constitutional symptoms.\par On examination, mucous membranes were pink, moist and anicteric. There was no lymphadenopathy. Significant findings were confined to the right lower limb where there was a large ill defined mass centred over the popliteal fossa. The mass was approximately 14cm by 7cm. The mass was firm, nontender, nonpulsatile, normal temperature, not attached to skin or muscle. There were no distal neurovascular deficits. CT of the chest, abdomen and pelvis were normal. MRI showed a large heterogeneous fatty mass surrounded by, but not arising from muscle measuring 24 cm by 12 cm by 8 cm. The mass was confined to the posterior compartment of the thigh and popliteal fossa but did not invade the knee joint. Two open biopsies returned an inconclusive result. In consultation with the patient, a wide local excision of the mass was performed (see Figures {\ref 1 and 2}). Histology of the excision revealed a well differentiated liposarcoma with microscopic involvement of one of the surgical margins. The Oncologists deemed it unnecessary to offer chemotherapy. The offer of radiotherapy was turned down by the patient because he was unwilling to face the potential complications of this treatment. At two years follow-up, he had shown no clinical evidence of recurrence locally or by metastasis. He was however unable to afford an MRI or CT to allow for radiological assessment of recurrence. \section[{III.}]{III.} \section[{Discussion}]{Discussion}\par Soft tissue sarcomas are heterogeneous, malignant tumours \hyperref[b4]{[5,}\hyperref[b5]{6]}. In relation to other types of cancer they are relatively rare where 5000 new cases are diagnosed yearly \hyperref[b6]{[7]}, representing about 1\% of all newly diagnosed neoplasms \hyperref[b7]{[8,}\hyperref[b8]{9]}. Liposarcoma constitutes about 9 to 18\% of all soft tissue sarcomas, second only to malignant fibrous histiocytoma \hyperref[b9]{[10,}\hyperref[b10]{11,}\hyperref[b12]{12]}. Liposarcomas may be defined as malignant mesenchymal tumours consisting of lipoblasts \hyperref[b10]{[11]}. They originate in the connective tissue and their name reflects the fact that variable amounts of adipose tissue are found within the tumour \hyperref[b13]{[13]}. Since sarcomas, in general, are very rare, there is not much literature on the prognostic factors and optimal treatment of liposarcomas \hyperref[b2]{[3]}. Compared to other malignant tumours in the extremity, it is uncommon \hyperref[b14]{[14]}.( D D D D )\par H iposarcoma is the most common histology of soft tissue sarcomas accounting for approximately 20 to 30\% of all sarcomas in adults \hyperref[b0]{[1,}\hyperref[b1]{2]}. Despite soft tissue and skeletal tissue being the most abundant tissue in the body, soft tissue sarcomas accounts for 1\% of neoplasms \hyperref[b2]{[3,}\hyperref[b3]{4]}. Prognostic features and subsequent clinical behaviour of soft tissue sarcoma are said to be associated with histology and anatomical distribution \hyperref[b2]{[3]}. These tumours often grow to large sizes, thus their management presents major challenges \hyperref[b3]{[4]}. The following case is presented to discuss the prognostic factors affecting the clinical behaviour of liposarcoma post limb sparing surgery. \section[{L}]{L}\par Liposarcomas occur mainly in adults \hyperref[b16]{[15,}\hyperref[b17]{16]} with its incidence peaking between 40 and 60 years with a slight predominance towards men \hyperref[b10]{[11,}\hyperref[b13]{13]}. It is much more commonly seen in Caucasians than blacks {\ref [17]}.\par Although it occurs at any age, and at any site \hyperref[b7]{[8]}, there is a paucity of data in children due to the rarity in this group \hyperref[b18]{[18]}. In both age groups, the thigh is the most frequent location \hyperref[b13]{[13,}\hyperref[b14]{14,}\hyperref[b18]{18,}\hyperref[b19]{19,}\hyperref[b20]{20]}, however they may also arise in the inguinal area and popliteal fossa \hyperref[b13]{[13,}\hyperref[b14]{14]}. Tumours in the popliteal fossa, such as the index case, are likely to be malignant \hyperref[b21]{[21]}. Other factors suggesting malignancy in the index case was a mass greater than 5 cm and a deep seated mass \hyperref[b6]{[7]}. Attachments to other structures also suggest malignancy. A mass is commonly the only symptom which may grow intermittently (index case) or progress steadily \hyperref[b4]{[5,}\hyperref[b20]{20]}. In comparison to other soft tissue sarcomas, liposarcomas tend to be large partially because the patient tends not to have other symptoms and they often have a deep location which may not allow the patient to appreciate the mass earlier \hyperref[b4]{[5,}\hyperref[b13]{13,}\hyperref[b20]{20]}. Both are possible reasons why the patient's mass grew to be large.\par Many different typing systems have been described \hyperref[b0]{[1,}\hyperref[b19]{19,}\hyperref[b22]{22,}\hyperref[b23]{23]}. The most commonly used system is Enzinger and Weiss \hyperref[b19]{[19,}\hyperref[b24]{24]}. The system recognises four variants of liposarcoma: well differentiated, myxoid, round cell and pleomorphic. The importance of the histological subtypes cannot be understated in terms of being a prognostic factor \hyperref[b16]{[15,}\hyperref[b24]{24,}\hyperref[b25]{25,}\hyperref[b26]{26]}. Well differentiated is the most common subtype \hyperref[b10]{[11,}\hyperref[b27]{27,}\hyperref[b29]{28]}. They tend to arise in the limbs or retro-peritoneum in the middle aged or elderly population accounting for greater than 50\% of reported cases \hyperref[b2]{[3,}\hyperref[b10]{11]}. This subtype is low grade and often is grossly very large, that is, greater than 20 cm \hyperref[b29]{[28]}. This was the subtype in the index case. Histologically it is characterised by proliferation of mature appearing adipocytes with variable numbers of atypical hyperchromatic cells either between the adipocytes or within dense fibrous septae {\ref [17]}.\par The second most common groups are the myxoid and round cells (30-40\% of all liposarcomas) which are seen in a younger population \hyperref[b10]{[11,}\hyperref[b30]{29]}. Asano 2012 reviewed information on 58 patients with myxoid and round cell tumours. The median age at presentation was 46 years old (range; 18-80 years). It is felt that the myxoid and round cells types are a continuum of a single subtype \hyperref[b19]{[19,}\hyperref[b24]{24,}\hyperref[b27]{27,}\hyperref[b29]{28]}. The higher the proportion of the round cell component is the worse the outcome \hyperref[b19]{[19,}\hyperref[b27]{27]}, with higher rates of metastasis \hyperref[b24]{[24,}\hyperref[b30]{29]}. There are two forms of myxoid tumour: The first is a well differentiated liposarcoma subtype which is similar to the well differentiated histological group, and the second form is characterised by distinctive genetic reciprocal translocation of two genes.\par De-differentiation of a well differentiated subtype may be due to a clonal evolution in which local foci of other cells are found such as malignant fibrous histocytoma \hyperref[b14]{[14,}\hyperref[b29]{28]}. De-differentiated and pleomorphic subtypes accounts for approximately 5\%, occurring in older patients and presenting in the limbs or retroperitoneum \hyperref[b10]{[11,}\hyperref[b30]{29]}. The pleomorphic subtype is most commonly seen in patients in their fourth decade \hyperref[b19]{[19]}. It has the worst prognosis based on disease free survival rates of 39\% at ten years \hyperref[b24]{[24,}\hyperref[b32]{30]}, and recurs in a third of cases \hyperref[b24]{[24]}.\par Histology affects subsequent clinical behaviour where low grade lesions (well differentiated) are associated with high local recurrence rates but have almost no propensity to metastasize. Poorly differentiated or high grade tumours are often clinically aggressive with a high incidence of local recurrence as well as distant metastasis \hyperref[b2]{[3,}\hyperref[b12]{12,}\hyperref[b33]{31]}. Although the different subgroups have different clinical courses in terms of clinical features and survival outcome, current clinical practice has not been optimised according to different histological subtypes and clinical protocols \hyperref[b2]{[3]}. Specific treatment protocols are lacking in the literature for liposarcoma other than treatment with wide resection {\ref [17]}. Treatment decisions and prognosis are based on a classification system that depends on morphological and genetic features of the tumour \hyperref[b4]{[5,}\hyperref[b34]{32]}. Kim et al \hyperref[b2]{[3]} looked at defining the distinctive clinical features by assessing prognostic factors in 94 liposarcoma patients. His multivariate analysis demonstrated that histological subtype was an index prognostic factor for survival. Higher grade tumours (de-differentiated, round cell, pleomorphic) were associated with a fivefold increase in( D D D D ) \section[{H}]{H}\par Diagnosis of liposarcoma is now less common because of stricter diagnostic criteria. Tumours such as atypical lipoma, spindle cell lipomas and pleomorphic lipomas were all once previously categorised as liposarcoma \hyperref[b16]{[15]}]. Early diagnosis and referral to specialist centres are necessary for optimal outcome \hyperref[b4]{[5]}.\par The lung is the commonest site of early metastasis \hyperref[b20]{[20,}\hyperref[b22]{22,}\hyperref[b32]{30]} in all subtypes except the myxoid subtype which has a strong propensity for extrapulmonary metastasis, for example, spine, retroperitoneum and axilla \hyperref[b32]{[30]}. Patients with the myxoid subtype require a more careful follow-up including assessment of the thorax, retroperitoneum and abdomen \hyperref[b32]{[30]}. Dedifferentiation is associated with a 15-30\% rate of metastasis and an increase risk of local recurrence and increased death risk \hyperref[b13]{[13,}\hyperref[b29]{28]}. Radical excision is thus required to achieve local control plus or minus adjuvant radiotherapy \hyperref[b29]{[28]}. The pleomorphic type is also associated with an increased risk of local and distant spread \hyperref[b10]{[11,}\hyperref[b30]{29]}. The overall metastatic potential of liposarcoma therefore varies widely from 20-70\% \hyperref[b10]{[11,}\hyperref[b14]{14,}\hyperref[b24]{24]}. Comparison between studies is difficult because of small numbers of patients and the wide variety of the subtypes \hyperref[b32]{[30]}. mortality rates compared with the well differentiated subtype. Zagars et al \hyperref[b24]{[24]} found that the most important factor influencing outcome in terms of local control, metastasis or survival rates was histological subtype. Berlin et al \hyperref[b36]{[33]} and Lietman et al {\ref [17]} found a strong association between disease specific survivorships and grade.\par Despite there being the same universal guidelines in managing extremity sarcomas, management must be individualised \hyperref[b38]{[34]}. Management however remains controversial \hyperref[b3]{[4]}. A multidisciplinary team approach allows for streamlining the complexities and intricacies of treatment and thus providing optimal treatment \hyperref[b3]{[4,}\hyperref[b38]{34]}. Goals include eradicating local disease, control of metastasis and salvaging a functional limb without compromising survival \hyperref[b3]{[4,}\hyperref[b4]{5]}. Prior to the use of radiotherapy, amputation was a standard therapeutic treatment \hyperref[b4]{[5,}\hyperref[b39]{35]}.\par Radiation has been proven to facilitate local control and when used in combination with limb sparing surgery has decreased the need for amputation \hyperref[b4]{[5,}\hyperref[b5]{6,}\hyperref[b24]{24]}. Patients such as the index case with inadequate margins may benefit from adjuvant therapy \hyperref[b5]{[6]}. In cases where a marginally resectable tumour is present, neoadjuvant therapy may increase the likelihood of a margin negative resection with subsequent preservation of function \hyperref[b38]{[34]}. The potential wound complications \hyperref[b38]{[34]} and the potential for radiation induced sarcoma which is typically seen two to three years post treatment \hyperref[b10]{[11]} dissuaded the patient from opting for radiotherapy.\par Grossly positive margins have a significantly worse prognosis compared with negative or microscopic positive margins \hyperref[b40]{[36]}. Conversely when adequate surgical margins are achieved, local recurrence is unlikely even in high grade tumours, making radiotherapy unnecessary in these cases \hyperref[b36]{[33,}\hyperref[b41]{37]}. The likelihood of local recurrence is partially related to whether the excision is marginal, wide or radical \hyperref[b41]{[37]}. Although many studies recommended a margin of at least 2cm of gross margins around the tumour, this is usually limited by a normal critical structure \hyperref[b41]{[37]}. Most liposarcomas in the extremity cannot be excised with a wide margin, but one should aim for at least a marginal resection \hyperref[b13]{[13]}. Despite positive margins being a risk factor for local recurrence, overall survival is unaffected \hyperref[b4]{[5,}\hyperref[b41]{37]}. This was the rationale for performing a marginal resection in some areas of the tumour in the index case. Leaving close margins near vital structures are acceptable for a limb salvage procedure \hyperref[b4]{[5]}. Baldini et al \hyperref[b41]{[37]} in their study of 74 sarcoma patients, 23 of which had liposarcoma, were all treated with excision alone. Six patients had positive margins. None of the six patients had local recurrence. The four patients with recurrence had histological evidence of tumour involvement less than 1cm within the resection margins. He found no relationship between recurrence and tumour grade, stage and depth, on further analysis though the study had limited statistical power. Ribuffo et al \hyperref[b43]{[38]} in reviewing liposarcoma in the thigh found no correlation between histological grade, surgical treatment and progression of disease. Conversely, Orson et al \hyperref[b33]{[31]} looked at 211 cases with a mean age of 52.9 years and found a 45\% variation in survival rates due to differences in histological grade, Enneking stage and tumour size. Various soft tissue reconstructive procedures have allowed for more aggressive resection leading to a lower likelihood of an intralesional resection \hyperref[b3]{[4,}\hyperref[b4]{5]}. Incompletely excised tumour may be subsequently re-excised inclusive of the prior incision followed by radiation therapy \hyperref[b5]{[6,}\hyperref[b14]{14,}\hyperref[b24]{24]}. With the index case refusing radiation therapy, he had been counselled on the need for re-excision once there is future evidence of recurrence. In the index case's favour, is the fact that no patient had demised solely to local disease in Linehan et al \hyperref[b12]{[12]} study as microscopic margins were not a predictor of local recurrence when managed with adjuvant radiotherapy.\par Sarcomas in general often appear grossly to be contained in a well-defined capsule but microscopic disease is often beyond the psuedocapsule, reactive zone, prior biopsy site scar and a cuff normal tissue via a longitudinal incision \hyperref[b4]{[5,}\hyperref[b38]{34]}.\par Although limb sparing surgery plus or minus radiotherapy have shown good results, the role of chemotherapy remains controversial \hyperref[b14]{[14]}. Adjuvant chemotherapy is meant to eradicate micrometastasis with the ultimate goal of prolonging time to recurrence and overall survival {\ref [17]}. Lietman et al {\ref [17]} performed a thorough literature search and found no randomised prospective studies analysing the effectiveness of various chemotherapy regimes, protocols or indications in the treatment of liposarcoma. Chemotherapy sensitivity varies significantly between liposarcoma subtypes with a higher response rate in the myxoid and round cell subtypes compared with the well differentiated subtype \hyperref[b34]{[32]}. Eilber et al \hyperref[b44]{[39]} found that ifosfamide based treatment in liposarcoma patients improved disease free survival states in patients with tumours greater than 10 cm (such as the index case) however there is little data to support use of chemotherapy in low grade liposarcoma because of their low metastatic spread potential \hyperref[b13]{[13]}.\par Location has been found to be an independent prognostic factor, since liposarcomas in the extremity has a better prognosis than retroperitoneal liposarcoma \hyperref[b12]{[12,} {\ref 17,}\hyperref[b23]{23]} \section[{H}]{H}\par In a 20 year retrospective review of 63 patients with liposarcoma; age, gender and tumour size were not shown to be statistically significant in terms of patient survivorship however, it was felt that the sample size was too small to make a definitive conclusion {\ref [17]}. Older age was a poor prognostic factor in some studies \hyperref[b23]{[23,}\hyperref[b36]{33]}.\par In most soft tissue sarcomas, recurrence occurs within two years. Follow up every three months with clinical and radiological imaging via MRI or ultrasound is recommended to identify local recurrence and chest CT for pulmonary metastasis \hyperref[b4]{[5,}\hyperref[b41]{37]}. If no lesion is identified, review may be six monthly after 2 to 3 years. There is as yet no clinical evidence of local recurrence in the index case. Since the adjuvant radiotherapy has been refused by the patient, he will be monitored clinically and radiologically and if recurrence occurs, reexcision will hopefully treat recurrence in this margin positive patient. Based on the well differentiated subtype, the index case is unlikely to have metastasis or mortality even if recurrence does occur. With improved understanding of patterns of recurrence in extremity liposarcoma, there will be earlier identification of subclinical metastatic disease thus allowing aggressive salvage treatment and improved overall survival \hyperref[b32]{[30]}. Dalal et al \hyperref[b23]{[23]} have published subtype specific liposarcoma prognostic nomograms that can efficiently integrate multiple prognostic variables which allow one to predict the probability of recurrence and death. This information is useful in counselling patients and in some cases to reassure \hyperref[b23]{[23]}. This also allows high risk patients to be identified and undergo intense surveillance and be considered for adjuvant or neoadjuvant therapy \hyperref[b23]{[23]}.\par In a very recent study, Knebel et al \hyperref[b45]{[40]} conducted a retrospective study on 133 patients with a diagnosis of liposarcoma. The median age was 55.1 years (14-86 years). Upon analysing the data he concluded that the histological subtype, tumour size, presence of metastasis, local recurrence post resection and negative resection margins were all independent factors which determined disease specific survival.\par IV. \section[{Conclusion}]{Conclusion}\par The histological subtype and resection margin status have been found to be independently associated with disease specific survival. Adjuvant radiotherapy has been found to have a bigger impact on overall survival rates as well as disease free survival, in low grade sarcomas than high grade ones.\begin{figure}[htbp] \noindent\textbf{12}\includegraphics[]{image-2.png} \caption{\label{fig_0}Fig. 1 Fig. 2}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-3.png} \caption{\label{fig_1}}\end{figure} \footnote{Prognostic Factors Affecting Management of Liposarcoma 3 © 2017 Global Journals Inc. (US) Year 2017} \footnote{© 2017 Global Journals Inc. (US)Year 2017} \backmatter \begin{bibitemlist}{1} \bibitem[ Singapore Med J]{b15}\label{b15} \textit{}, \textit{Singapore Med J} 50 (9) p. . \bibitem[Ortho]{b37}\label{b37} \textit{}, Acta Ortho , Scand . 61 p. . \bibitem[Springfield ()]{b13}\label{b13} \textit{}, D Springfield . \textit{Clin Orthop Relat Res} 1993. (289) p. . \bibitem[Mccormick et al. ()]{b25}\label{b25} \textit{}, D Mccormick , T Mentzel , A Beham , C D Fletcher . \textit{J Surg Pathol} 1994. 18 (12) p. . \bibitem[Enzinger and Weiss ()]{b10}\label{b10} \textit{}, F M Enzinger , S W Weiss . 1995. Liposarcoma. \bibitem[Smith et al. ()]{b30}\label{b30} \textit{}, T A Smith , K A Easley , J R Goldblum . 1996. \bibitem[Mentzel and Fletcher ()]{b27}\label{b27} \textit{}, T Mentzel , C D Fletcher . 1997. \bibitem[Baldini et al. ()]{b41}\label{b41} \textit{}, E H Baldini , J Goldberg , C Jenner , J B Manola , G D Demetri , C D Fletcher . 1999. \bibitem[De Vreeze et al. ()]{b34}\label{b34} \textit{}, R S De Vreeze , D De Jong , P M Nederlof , A Ariaens , I H Tielen , L Frenken . 2010. \bibitem[Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience Ann Surg Oncol]{b35}\label{b35} ‘Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience’. \textit{Ann Surg Oncol} 17 (3) p. . \bibitem[Jemal et al. ()]{b1}\label{b1} ‘Cancer statistics CA’. A Jemal , R Siegal , E Ward , Y Hao , J Xu , T Murray . \textit{A Cancer Journal for Clinicians} 2008. 58 (2) p. . \bibitem[Ferrari et al. ()]{b18}\label{b18} ‘Childhood liposarcoma: a single-institutional twenty-year experience’. A Ferrari , M Casanova , F Spreafico , R Luksch , M Terenziani , G Cefalo . \textit{Pediatr Hematol Oncol} 1999. 16 (5) p. . \bibitem[Wu and Montgomery ()]{b29}\label{b29} ‘Classification and pathology’. J M Wu , E Montgomery . \textit{Surg Clin North Am} 2008. 88 (3) p. . \bibitem[Ribuffo et al. ()]{b43}\label{b43} ‘Controversial issues in diagnosis of liposarcomas of the thigh. A report of 18 cases’. D Ribuffo , M G Onesti , E Elia , V Cucchiara , M Valeriani , N Scuderi . \textit{Scand J Plast Reconstr Surg Hand Surg} 1998. 32 (3) p. . \bibitem[Dedifferentiated myxoid liposarcoma: a clinicopathological study suggesting a closer relationship between myxoid and well-differentiated liposarcoma Histopathology]{b28}\label{b28} ‘Dedifferentiated myxoid liposarcoma: a clinicopathological study suggesting a closer relationship between myxoid and well-differentiated liposarcoma’. \textit{Histopathology} 30 (5) p. . \bibitem[Weiss et al.]{b11}\label{b11} \textit{Enzinger and Weiss's Soft Tissue Tumors, 4 th ed}, S W Weiss , J R Goldblum , F M Enzinger . St Louis; Mosby. p. . \bibitem[Cheng et al. ()]{b22}\label{b22} ‘Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma’. E Y Cheng , D S Springfield , H J Mankin . \textit{Cancer} 1995. 75 (5) p. . \bibitem[Linehan et al. ()]{b12}\label{b12} ‘Influence of biologic factors and anatomic site in completely resected liposarcoma’. D C Linehan , J J Lewis , D Leung , M F Brennan . \textit{J Clin Oncol} 2000. 18 (8) p. . \bibitem[Steinau et al. ()]{b21}\label{b21} \textit{Limb Salvage in Malignant Tumors. Seminars in Plastic Surgery. Extremity-Saving Surgery and Reconstruction: From Microsurgery Reconstruction to Transplantation}, H-U Steinau , A Daigeler , S Langer , L Steinstrasser , J Hauser , O Goert . 2010. 24 p. . \bibitem[Reszel et al. ()]{b20}\label{b20} ‘Liposarcoma of the extremities and limb girdles. A study of two hundred twenty-two cases’. P A Reszel , E H Soule , M B Coventry . \textit{J Bone Joint Surg Am} 1966. 48 (2) p. . \bibitem[Ng and Tan ()]{b14}\label{b14} \textit{Liposarcoma of the extremities: a review of the cases seen and managed in a major tertiary}, Y C Ng , M H Tan . 2009. Singapore. \bibitem[Orson et al. ()]{b33}\label{b33} ‘Liposarcoma of the musculoskeletal system’. G G Orson , F H Sim , H M Reiman , W F Taylor . \textit{Cancer} 1987. 15 (6) p. . \bibitem[Gustafson et al. ()]{b19}\label{b19} ‘Liposarcoma: a population based epidemiologic and prognostic study of features of 43 patients, including tumor DNA content’. P Gustafson , A Rydholm , H Willen , B Baldetorp , M Ferno , M Akerman . \textit{Int J Cancer} 1993. 55 p. . \bibitem[Kim et al. ()]{b2}\label{b2} ‘Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy’. H S Kim , J Lee , S Y Yi , H J Jun , Y L Choi , G H Ahn . \textit{Biomedical central Cancer} 2009. 9 p. 205. \bibitem[Zagars et al. ()]{b24}\label{b24} ‘Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy’. G K Zagars , M S Goswitz , A Pollack . \textit{Int J Radiat Oncol Biol Phys} 1996. 36 (2) p. . \bibitem[Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk J Clin Oncol]{b42}\label{b42} ‘Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk’. \textit{J Clin Oncol} 17 (10) p. . \bibitem[Peterson et al. ()]{b9}\label{b9} ‘malignant fatty tumors: classification, clinical course, imaging appearance and treatment’. J J Peterson , M J Kransdorf , L W Bancroft , M I O'connor . \textit{Skeletal Radiol} 2003. 32 (9) p. . \bibitem[Hueman et al. ()]{b38}\label{b38} ‘Management of Extremity Soft Tissue Sarcomas’. M T Hueman , K Thornton , J M Herman , N Ahuja . \textit{Surg Clin N Am} 2008. 88 (3) p. . \bibitem[Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma Am J Surg Pathol]{b31}\label{b31} ‘Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma’. \textit{Am J Surg Pathol} 20 (2) p. . \bibitem[Pearlstone et al. ()]{b32}\label{b32} ‘Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up’. D B Pearlstone , P W Pisters , R J Bold , B W Feig , K K Hunt , A W Yasko . \textit{Cancer} 1999. 85 (1) p. . \bibitem[Sadoski et al. ()]{b40}\label{b40} ‘Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues’. C Sadoski , H D Suit , A Rosenberg , H Mankin , J Efird . \textit{J Surg Oncol} 1993. 52 (4) p. . \bibitem[Prognostic Factors Affecting Management of Liposarcoma]{b46}\label{b46} \textit{Prognostic Factors Affecting Management of Liposarcoma}, \bibitem[Knebel et al. ()]{b45}\label{b45} ‘Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years’. C Knebel , U Lenze , F Pohlig , F Lenze , N Harrasser , C Suren , H M L Mühlhofer . \textit{BMC Cancer} 2017. 17 p. 410. \bibitem[Leow et al. ()]{b3}\label{b3} ‘Reconstructive treatment following resection of high-grade soft-tissue sarcomas of the lower limb’. A M Leow , A S Halim , Z Win . \textit{J Orth Surg} 2005. 13 (1) p. . \bibitem[Gilbert et al. ()]{b4}\label{b4} ‘Soft tissue sarcoma’. N F Gilbert , C P Cannon , P P Lin , O L Valerae . \textit{J Am Acad Orthop Surg} 2009. 17 (1) p. . \bibitem[Lewis and Brennan ()]{b8}\label{b8} ‘Soft tissue sarcomas’. J J Lewis , M F Brennan . \textit{Curr Probl Surg} 1996. 33 (10) p. . \bibitem[Sim et al. ()]{b6}\label{b6} ‘Soft-tissue tumours: diagnosis, evaluation, and management’. F H Sim , F J Frassica , D A Frassica . \textit{J Am Acad Orthop Surg} 1994. (4) p. . \bibitem[Dalal et al. ()]{b23}\label{b23} ‘Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk’. K M Dalal , M W Kattan , C R Antonescu , M F Brennan , S Singer . \textit{Ann Surg} 2006. 244 (3) p. . \bibitem[Berlin et al. ()]{b36}\label{b36} \textit{Surgery for soft tissue sarcoma in the extremities}, O Berlin , B Stener , L Angerval , L-G Kindblom , G Markhede , A Oden . 1990. (A multivariate analysis of the 6-26-year prognosis in 137 patients) \bibitem[Chandrasekar et al. ()]{b7}\label{b7} ‘The effect of an unplanned excision of a soft-tissue sarcoma on prognosis’. C R Chandrasekar , H Wafa , R J Grimer , S R Cater , R M Tillman , A Abudu . \textit{J Bone Joint Surg Br} 2008. 90 (2) p. . \bibitem[Eilber and Eckardt ()]{b44}\label{b44} ‘The impact of chemotherapy on the survival of patients with high grade extremity liposarcoma’. F C Eilber , J Eckardt . \textit{Ann surg} 2004. 240 (4) p. . \bibitem[Mendenhall et al. ()]{b5}\label{b5} ‘The management of adult soft tissue sarcomas’. W M Mendenhall , D J Indelicato , M T Scarborough , R A Zlotecki , C P Gibbs , N P Mendenhall . \textit{Am J Clin Oncol} 2009. 32 (4) p. . \bibitem[Chang et al. ()]{b26}\label{b26} ‘The prognostic value of histologic subtypes in primary extremity liposarcoma’. H R Chang , S I Hajdu , C Collin , M F Brennan . \textit{Cancer} 1989. 64 (7) p. . \bibitem[Kaushal and Citrin ()]{b39}\label{b39} ‘The role of radiation therapy in the management of sarcomas’. A Kaushal , D Citrin . \textit{Surg Clin North Am} 2008. 88 (3) p. . \bibitem[Weiss and Rao ()]{b17}\label{b17} \textit{Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of}, S W Weiss , V K Rao . 1992. (dedifferentiation) \bibitem[Lucas et al. ()]{b16}\label{b16} ‘Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases’. D R Lucas , A G Nascimento , B K Sanjay , M G Rock . \textit{Am J Clin Pathol} 1994. 102 (5) p. . \bibitem[Fletcher et al. ()]{b0}\label{b0} \textit{World Health Organisation classification of tumours pathology and genetics of tumours of soft tissue and bone}, C D M Fletcher , K K Umi , F Mertens . 2002. IARC Press. p. . \end{bibitemlist} \end{document}